Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Alzamend Neuro Inc (ALZN)

$1.16 +0.04 (3.57%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	4.41M
Revenue (ttm)	0.00
Net Income (ttm)	-4.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	378,000
Avg Vol	165,574
Day's Range	N/A - N/A
Shares Out	3.81M
Stochastic %K	32%
Beta	0.14
Analysts	Sell
Price Target	$25.00

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology

Sector: Healthcare

Phone: 844 722 6333

Website: www.alzamend.com

Address:

3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States

Zboquid Jul. 2 at 11:08 PM

$ALZN AH Pumped and Dumped

0 · Reply

Dcvfin Jul. 2 at 2:00 PM

$ALZN this one looks bad 4 guys No money Oh boy

0 · Reply

Zboquid Jul. 2 at 11:37 AM

$ALZN 🧠

0 · Reply

m2139m Jul. 2 at 12:37 AM

$ALZN 🙃🙃

0 · Reply

ipaidtoomuch Jul. 1 at 8:43 PM

$ALZN I do not see any new filings anyone?

1 · Reply

MarketsParadise Jul. 1 at 8:16 PM

Small caps heating up, We are seeing some big runners lately. Take a look at ticker DRCT 💎 I believe this is the next monster runner waiting to be found: DRCT 💎 • 600K share float! • AI-powered digital advertising & marketing drive. • Extremely thin chart. • Any sustained buying pressure we look for the 5$+. $ALZN $GUTS $AURE $MMA ..33

0 · Reply

ipaidtoomuch Jul. 1 at 7:39 PM

$ALZN and ready set

0 · Reply

m2139m Jul. 1 at 7:01 PM

$ALZN

0 · Reply

ipaidtoomuch Jul. 1 at 6:55 PM

$ALZN 1.13 I am an idiot.

0 · Reply

ipaidtoomuch Jul. 1 at 5:50 PM

$ALZN well that escalated quickly. thats all for me for now

0 · Reply

Alzamend Neuro’s AL001 shows “encouraging” data in Phase II brain trial

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

2026-03-26T12:07:28.000Z - 3 months ago

Alzamend Neuro reports ‘positive’ data from Phase II clinical trial of AL001

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Alzamend Neuro Slides: Corporate presentation

2026-03-16T12:15:09.000Z - 3 months ago

Alzamend Neuro initiates Phase II trial of AL001 study

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

Mar 11, 2026, 8:00 AM EDT - 4 months ago

Alzamend Neuro Quarterly report: Q3 2026

Feb 26, 2026, 7:00 AM EST - 4 months ago

Alzamend Neuro Proxy statement: Proxy filing

Feb 26, 2026, 7:00 AM EST - 4 months ago

Alzamend Neuro Proxy statement: Proxy filing

Feb 9, 2026, 7:00 AM EST - 5 months ago

Alzamend Neuro Proxy statement: Proxy filing

Dec 9, 2025, 7:00 AM EST - 7 months ago

Alzamend Neuro Quarterly report: Q2 2026

2025-11-19T13:05:35.000Z - 8 months ago

Alzamend Neuro completes clinical portion of Phase II clinical study of AL001

Nov 19, 2025, 8:00 AM EST - 8 months ago

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

Sep 10, 2025, 8:00 AM EDT - 10 months ago

Alzamend Neuro Quarterly report: Q1 2026

2025-07-28T12:21:07.000Z - 1 year ago

Alzamend Neuro to present at Military Health System Research Symposium

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

2025-07-23T12:11:32.000Z - 1 year ago

Alzamend Neuro reports FY25 net cash provided by financing activities of $10.4M

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Annual report: Q4 2025

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Earnings release: Q4 2025

2025-06-16T12:10:25.000Z - 1 year ago

Alzamend Neuro announces final closing of $5M private placement

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule

2025-05-29T20:25:00.000Z - 1 year ago

Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update

2025-05-29T12:10:58.000Z - 1 year ago

Alzamend Neuro doses first patient in Phase II study of AL001

May 29, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

2025-05-19T12:10:49.000Z - 1 year ago

Alzamend Neuro enrolls first patient in Phase II trial of AL001

May 19, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

2025-05-13T12:17:57.000Z - 1 year ago

Alzamend Neuro initiates first Phase II trial of AL001

May 13, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

2025-05-09T23:50:59.000Z - 1 year ago

Alzamend Neuro trading halted, news pending

2025-05-08T12:24:11.000Z - 1 year ago

Alzamend Neuro announces 1-for-9 reverse stock split

May 8, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Reverse Stock Split

2025-05-07T12:25:56.000Z - 1 year ago

Alzamend Neuro partners with Mint Labs to support five upcoming trials

May 7, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Registration statement: Registration filing

2025-03-25T18:40:14.000Z - 1 year ago

Alzamend Neuro announces initiation date of Phase II trial of AL001

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer's Disease to take Place at Massachusetts General Hospital

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing

2025-03-18T12:16:21.000Z - 1 year ago

Alzamend Neuro announces initiation date of Phase II trial of AL001

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing

2025-03-13T20:36:07.000Z - 1 year ago

Alzamend Neuro files to sell 75.775M shares of common stock for holders

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Registration statement: Registration filing

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Post-Traumatic Stress Disorder to take Place at Massachusetts General Hospital

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Quarterly report: Q3 2025

Mar 4, 2025, 8:10 AM EST - 1 year ago

Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Bipolar Disorder to take Place at Massachusetts General Hospital

Feb 28, 2025, 7:00 AM EST - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing

Feb 25, 2025, 8:00 AM EST - 1 year ago

Alzamend Neuro Announces Initiation Date of First Phase II Clinical Trial of AL001 to take Place at Massachusetts General Hospital

Dec 11, 2024, 7:00 AM EST - 1 year ago

Alzamend Neuro Quarterly report: Q2 2025

Dec 11, 2024, 7:00 AM EST - 1 year ago

Alzamend Neuro Earnings release: Q2 2025

Sep 11, 2024, 8:00 AM EDT - 1 year ago

Alzamend Neuro Quarterly report: Q1 2025

Aug 19, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ABBV

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Annual report: Q4 2024

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Registration statement: Registration filing

Jun 26, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Registration statement: Registration filing

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Registration statement: Registration filing

May 31, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing

May 10, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing

May 7, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

May 1, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Quarterly report: Q3 2024

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing

Dec 15, 2023, 7:00 AM EST - 2 years ago

Alzamend Neuro Quarterly report: Q2 2024

Sep 13, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Quarterly report: Q1 2024

Sep 1, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing

Aug 24, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing

Aug 10, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing

Aug 2, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Registration statement: Registration filing

Jul 27, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Annual report: Q4 2023

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Altasciences Completes Clinical Portion of Alzamend Neuro's Phase IIa Multiple Ascending Dose Clinical Trial for Treatment of Dementia Related to Alzheimer's

Apr 4, 2023, 6:30 AM EDT - 3 years ago

Ault Alliance Announces Alzamend Neuro Has Initiated Its Phase I/IIA Trial for Its Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer's Type

Mar 31, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Quarterly report: Q3 2023

Dec 12, 2022, 7:00 AM EST - 3 years ago

Alzamend Neuro Quarterly report: Q2 2023

Nov 28, 2022, 6:30 AM EST - 3 years ago

BitNile Holdings Contemplates Exchange Offer to Acquire Shares of Its Common Stock

Nov 22, 2022, 8:05 AM EST - 3 years ago

In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Stephan Jackman, CEO Alzamend Neuro, Inc.

Nov 21, 2022, 7:27 PM EST - 3 years ago

BitNile Holdings Reports Third Quarter 2022 Financial Results, Including Revenue of $100 Million for the Nine Months Ended September 30, 2022, up 124% from the Prior Year's Nine-Month Period

Nov 1, 2022, 6:30 AM EDT - 3 years ago

BitNile Holdings Announces That Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Clinical Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Alzheimer's Disease

Sep 22, 2022, 8:00 AM EDT - 4 years ago

Alzamend Neuro Has Regained Compliance with Nasdaq's Minimum Bid Price Requirement

Sep 13, 2022, 8:00 AM EDT - 4 years ago

Alzamend Neuro Quarterly report: Q1 2023

Jul 19, 2022, 8:00 AM EDT - 4 years ago

Alzamend Neuro Annual report: Q4 2022

Mar 15, 2022, 8:00 AM EDT - 4 years ago

Alzamend Neuro Quarterly report: Q3 2022

Dec 13, 2021, 7:00 AM EST - 4 years ago

Alzamend Neuro Quarterly report: Q2 2022

Sep 30, 2021, 10:11 AM EDT - 5 years ago

Alzamend Neuro Receives Positive Pre-IND Response from FDA for AL002, a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patients' Immunological System to Combat Alzheimer's Disease

Sep 13, 2021, 8:00 AM EDT - 5 years ago

Alzamend Neuro Quarterly report: Q1 2022

Sep 13, 2021, 6:30 AM EDT - 5 years ago

Alzamend Neuro Announces Initiation of Phase I First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's Disease

Aug 4, 2021, 6:30 AM EDT - 5 years ago

Alzamend Neuro Announces Additional Investment Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Pursuant to the Securities Purchase Agreement with Digital Power Lending

Jul 30, 2021, 6:30 AM EDT - 5 years ago

Alzamend Neuro Announces Pre-IND Submission for AL002 as a Cell-Based Therapeutic Vaccine That Seeks to Restore the Ability of Patient's Immunological System to Combat Alzheimer's

Jul 29, 2021, 8:00 AM EDT - 5 years ago

Alzamend Neuro Annual report: Q4 2021

Jul 28, 2021, 3:07 PM EDT - 5 years ago

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase 1 Clinical Study Under Its Investigational New Drug Application for AL001 for Dementia Related to Alzheimer's Disease

Jul 23, 2021, 6:30 AM EDT - 5 years ago

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer's Disease

Jul 12, 2021, 6:00 AM EDT - 5 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 1, 2021, 6:30 AM EDT - 5 years ago

Alzamend Neuro Submits IND Application for AL001 for Dementia Related to Alzheimer's Disease

Jun 17, 2021, 4:30 PM EDT - 5 years ago

Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

Jun 16, 2021, 6:30 AM EDT - 5 years ago

Ault Global Holdings Announces Alzamend Neuro Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 5 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering

Zboquid Jul. 2 at 11:08 PM

$ALZN AH Pumped and Dumped

0 · Reply

Dcvfin Jul. 2 at 2:00 PM

$ALZN this one looks bad 4 guys No money Oh boy

0 · Reply

Zboquid Jul. 2 at 11:37 AM

$ALZN 🧠

0 · Reply

m2139m Jul. 2 at 12:37 AM

$ALZN 🙃🙃

0 · Reply

ipaidtoomuch Jul. 1 at 8:43 PM

$ALZN I do not see any new filings anyone?

1 · Reply

MarketsParadise Jul. 1 at 8:16 PM

0 · Reply

ipaidtoomuch Jul. 1 at 7:39 PM

$ALZN and ready set

0 · Reply

m2139m Jul. 1 at 7:01 PM

$ALZN

0 · Reply

ipaidtoomuch Jul. 1 at 6:55 PM

$ALZN 1.13 I am an idiot.

0 · Reply

ipaidtoomuch Jul. 1 at 5:50 PM

$ALZN well that escalated quickly. thats all for me for now

0 · Reply

ipaidtoomuch Jul. 1 at 5:47 PM

$ALZN collecting a few 1.13 we will see you do you.

0 · Reply

hiwatt Jul. 1 at 3:52 PM

$ALZN Looks like algorithms playing the news. When the news doesn't drop, the stock price does.

0 · Reply

Zboquid Jul. 1 at 1:04 PM

$ALZN Couple of phase 2 drugs in the pipeline wonder if there is a news leak on one of them

0 · Reply

Zboquid Jul. 1 at 11:39 AM

$ALZN $1.65 this AM

0 · Reply

Aussietradz Jul. 1 at 11:37 AM

$ALZN drop the news

0 · Reply

ChubbyPanda Jul. 1 at 11:25 AM

$ALZN this fucker ain't doing shit. Just a random mini-pump it seems.

0 · Reply

Stock_Catcher Jul. 1 at 11:22 AM

$ALZN perking

0 · Reply

m2139m Jul. 1 at 9:07 AM

$ALZN ?????????????

0 · Reply

Investing4Knowledge Jul. 1 at 3:04 AM

$ALZN - it’s going crazy in the overnight market 🔥 on watch tomorrow! 👀 $CAPR $QQQ $SPY

0 · Reply

hiwatt Jul. 1 at 2:04 AM

$ALZN Last year Alzn posted the first update for the "lithium in the brain study" on 4-3-25. The announced first patient dosed 1 month , 16 days later. The stock open up 120% and closed up 75% on the news and traded 77 million shares. It has now been 2 months, 14 days since they first posted the "BP"study on clinical trials, so is this run up impending clinical trial news?????

0 · Reply

Stock_Catcher Jul. 1 at 2:00 AM

Wealthy Wednesday Watchlist Overnight Gappers $DXF $ALZN $BTOG $SCKT $JEM

0 · Reply

artuskis Jul. 1 at 1:35 AM

$ALZN !!!

0 · Reply

1.0.0